Experience real-time quotes, in-depth charts, and analyst ratings

MARKET

SNY

Sanofi FR

NASDAQ

45.44

-0.67

-1.45%

Opening 15:59 04/18 EDT

OPEN

45.47

PREV CLOSE

46.11

HIGH

45.71

LOW

45.22

VOLUME

4.23M

TURNOVER

52 WEEK HIGH

57.82

52 WEEK LOW

42.63

MARKET CAP

113.44B

P/E (TTM)

19.16

QUEBEC'S INESSS RECOMMENDS BEYFORTUS FOR THE PREVENTION OF RSV FOR ALL INFANTS 8 MONTHS OF AGE AND YOUNGER

Reuters · 18h ago

SANOFI-AVENTIS CANADA INC.: SANOFI WORKING WITH QUEBEC PROVINCIAL AUTHORITIES TO MAKE BEYFORTUS AVAILABLE FOR 2024-25 RSV SEASON

Reuters · 18h ago

Maintaining Buy Rating on Sanofi: A Resilient Financial Outlook Despite Currency Headwinds

TipRanks · 1d ago

Amgen/AstraZeneca's Asthma Drug Tezspire Vs. Sanofi/Regeneron's Blockbuster Dupixent - Analyst Gives His Pick

Amgen provides update on results of the Phase 2a trial for Tezspire in chronic obstructive pulmonary disease. Tezepelumab numerically reduced the annualized rate of moderate or severe COPD exacerbations versus placebo by 17%. The reduction was not statistically significant.

Benzinga · 1d ago

Novartis Multiple Sclerosis Drug Kesimpta Shows Substantial Benefit Of Up To 6 Years

Novartis AG released data from the ALITHIOS open-label extension study showing sustained efficacy of first-line, continuous Kesimpta treatment for up to six years in recently diagnosed relapsing multiple sclerosis. The study showed 44% fewer relapses and reductions in MRI lesions.

Benzinga · 1d ago

Sanofi's Multiple Sclerosis Antibody Shows Reduction Of Disease Activity

Sanofi reports new data from a Phase 2 study in relapsing multiple sclerosis. The company's CD40L antibody, frexalimab, demonstrated sustained reduction of disease activity. Preliminary clinical results are promising with a low annual relapse rate, company says.

Benzinga · 1d ago

IGM BIOSCIENCES: UNDER AGREEMENT, WILL BE ELIGIBLE TO RECEIVE UP TO $1,065 MLN IN AGGREGATE DEVELOPMENT, REGULATORY AND COMMERCIAL MILESTONES/TARGET

Reuters · 1d ago

Sanofi's CD40L Antibody: New 48-Week Phase 2 Data Support Frexalimab's Potential For High Sustained Efficacy In Multiple Sclerosis

Frexalimab is a non-lymphocyte depleting treatment for relapsing multiple sclerosis. 96% of participants in a study had no new lesions and an annualized relapse rate of 0.04 after 48 weeks. Sanofi has initiated global phase 3 studies of the drug.

Benzinga · 1d ago

About SNY

Sanofi SA is a France-based healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme.

Webull offers Sanofi SA (ADR) stock information, including NASDAQ: SNY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SNY stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SNY stock methods without spending real money on the virtual paper trading platform.